AM-103

AM-103 is a drug that was developed for the treatment of inflammation and related conditions. It acts as a phosphodiesterase 4 (PDE4) inhibitor, which means it blocks the action of PDE4 enzymes. These enzymes are involved in the process of inflammation, so inhibiting them can help to reduce inflammation and the symptoms associated with it.

Mechanism of Action

AM-103 works by inhibiting the action of PDE4 enzymes. These enzymes are involved in the process of inflammation. By blocking their action, AM-103 can help to reduce inflammation and the symptoms associated with it.

Development and Clinical Trials

AM-103 was developed by the pharmaceutical company Almirall. It was tested in clinical trials for the treatment of chronic obstructive pulmonary disease (COPD), but development was discontinued in 2010.

See Also

• Phosphodiesterase 4 inhibitor
• Chronic obstructive pulmonary disease
• Inflammation

References

AM-103 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski